Benzodiazepine and Xanax Addiction in Veterans

More than 140,000 Veterans were receiving a benzodiazepine prescription on any given day in 2023, according to VA reporting, a figure that excludes veterans obtaining these medications through non-VA providers, informal sources, or the counterfeit pill market. Benzodiazepines are among the most widely prescribed psychiatric medications in the veteran population, and among the most misunderstood. A veteran who takes Xanax exactly as prescribed for two years is not making a reckless choice. But that veteran may still develop a physical dependency that creates serious medical risk, with no warning until the moment they try to stop.

Veteran benzodiazepine addiction sits at the intersection of military trauma, chronic pain management, and a prescribing history that, in many cases, did not prioritize long-term safety. At Hope Valley Health and Wellness in Wasilla, Alaska, a CARF-accredited residential treatment program serving veterans across Alaska and the lower 48, clinicians work with this population daily. What follows is a clinical account of how benzodiazepine dependency develops in veterans, why it is medically dangerous, and what effective treatment looks like.

How Veterans Got Prescribed Benzodiazepines

The story of benzodiazepine prescribing in veterans begins with an accurate diagnosis and an imperfect solution. Veterans returning from combat, and older veterans from Vietnam, Korea, and the Gulf War, presented to VA clinics with anxiety disorders, PTSD, and severe sleep disruption at rates that outpaced clinical capacity. Something needed to work quickly.

Benzodiazepines, including alprazolam (Xanax), clonazepam (Klonopin), lorazepam (Ativan), and diazepam (Valium), work quickly. They bind to GABA receptors and produce powerful sedation and anxiolysis. For a Service member experiencing hyperarousal, panic attacks, or complete inability to sleep, the short-term relief is real. That relief became the foundation of widespread prescribing.

According to VA clinical resources on PTSD treatment, benzodiazepines are not recommended as a first-line treatment for PTSD: the evidence base for their effectiveness in PTSD is weak, and the risk profile for long-term use is significant. But the gap between clinical guidelines and clinical practice has historically been wide, particularly in high-volume settings where a prescribing decision had to be made in a 20-minute appointment.

Research published in NCBI/PubMed examining VA prescribing patterns found that benzodiazepine prescribing to Service members with PTSD was common well into the 2010s despite evidence that these medications provided limited benefit for trauma symptoms and created substantial risk of dependency. Some veterans received benzodiazepines for years without being told that physical dependence was developing, or without a clear plan for how the medication would eventually be tapered.

The civilian medical system added another layer. Veterans using non-VA providers, whether because they lived far from a VA facility, VA wait times were prohibitive, or they did not qualify for VA care, encountered civilian prescribers who had no coordinated picture of what a veteran patient had already been prescribed. Benzodiazepines were prescribed again, sometimes alongside opioids, sometimes without awareness of what else the veteran was taking.

The result is a population of veterans who did not seek out benzodiazepines as a drug of abuse. They received them from doctors, took them as instructed, and found themselves dependent, through a pathway that felt like following medical advice, because it was.

The Tolerance and Dependency Cycle Nobody Explained

The mechanism of benzodiazepine tolerance is rarely explained in plain terms at the point of prescription. Benzodiazepines enhance the activity of gamma-aminobutyric acid (GABA), the brain’s primary inhibitory neurotransmitter. When GABA activity is artificially elevated, the brain compensates by reducing the sensitivity of GABA receptors. The same dose now produces a diminished effect, and the medication that was working is maintaining a new baseline that is chemically dependent on the drug’s presence.

This is not a sign of weakness. It is a normal neurological adaptation that happens in nearly everyone who uses benzodiazepines consistently for more than a few weeks. Physical dependence can establish itself within four to six weeks of daily use, faster in veterans with alcohol use history, since alcohol operates through the same receptor system.

What veterans frequently were not told is that this dependency requires careful medical management to reverse. Stopping benzodiazepines is not a matter of willpower. When the drug is removed, the system that reduced its own GABA activity to compensate is suddenly operating without the supplement it has adjusted to expect. For many veterans, the first recognizable sign is interdose withdrawal (anxiety or agitation when a dose wears off or is missed), which is often interpreted, by both the veteran and the prescriber, as the original anxiety returning. The medication is now treating a problem it has partially created.

This cycle of tolerance, escalating dose, physical dependency, and interdose symptoms mistaken for the original diagnosis is how many Service members end up on higher doses for longer periods than anyone intended. For an overview of how benzodiazepine dependency intersects with other substances, see our resource on polysubstance abuse in Veterans.

Benzo Withdrawal: Why It Is Medically Dangerous

Benzodiazepine withdrawal is one of a small number of drug withdrawal syndromes that can be directly fatal. This is not a scare tactic. It is a clinical fact that should inform every decision about how a veteran stops using benzodiazepines.

Alcohol and benzodiazepines share a withdrawal mechanism because they share a mechanism of action: both work primarily on GABA receptors. When a brain that has become physically dependent on either substance is abruptly deprived of it, the result is a neurological hyperexcitability that manifests across a spectrum from uncomfortable to life-threatening.

Mild to moderate benzodiazepine withdrawal symptoms include anxiety (often more severe than the original presenting anxiety), insomnia, irritability, tremor, sweating, elevated heart rate and blood pressure, and muscle tension. These symptoms are intensely uncomfortable but are not immediately dangerous in and of themselves.

Severe benzodiazepine withdrawal symptoms can include seizures: tonic-clonic seizures that can occur without warning in a person who has never had a seizure disorder. They can also include delirium: a state of acute confusion with hallucinations and disorientation that represents a neurological emergency. Both of these outcomes are possible in someone who simply stops taking their Xanax prescription after prolonged use.

A 2019 analysis published through NCBI examining benzodiazepine withdrawal severity documented that the risk of severe withdrawal is correlated with daily dose, duration of use, and the half-life of the specific benzodiazepine. Short-acting benzodiazepines like Xanax produce more rapid and often more intense withdrawal than longer-acting ones like Valium. A Service member who has been taking Xanax multiple times daily for two years faces a substantially different withdrawal risk profile than someone who took it occasionally.

The implication is direct: benzodiazepine withdrawal is not safe to attempt without medical supervision, and it is not safe at home. For Veterans, who are disproportionately likely to live in rural areas with limited access to emergency medical care, including much of Alaska, the stakes of an unmanaged withdrawal seizure are particularly high. Our medical detox program for Veterans is staffed to manage benzodiazepine withdrawal safely, including the monitoring protocols and medication management required to reduce seizure risk throughout the taper process.

The Benzo-Opioid Combination: Elevated Overdose Risk

No discussion of benzodiazepine risk in the Veteran population is complete without addressing the combination of benzodiazepines and opioids. This combination is common among Veterans. It is also one of the most dangerous drug combinations in clinical medicine.

Both benzodiazepines and opioids suppress the central nervous system. Opioids reduce the brain’s drive to breathe; benzodiazepines reduce neurological excitability across a broader range of brain circuits, including the respiratory centers in the brainstem. When both are present, the respiratory suppression is not additive; it is synergistic. The combined effect exceeds what either drug produces alone.

The FDA’s Black Box Warning on combining opioids and benzodiazepines states explicitly that this combination can result in profound sedation, respiratory depression, coma, and death. SAMHSA drug abuse warning data consistently shows that benzodiazepine-opioid combinations are among the most frequently identified co-occurring substances in fatal overdoses.

The risk does not require illicit use. A Veteran taking prescribed Xanax for anxiety and prescribed hydrocodone for back pain, from two physicians without full visibility into each other’s decisions, is at elevated overdose risk through entirely legal channels. Medication reconciliation and a complete clinical picture are non-negotiable in benzodiazepine treatment for this reason.

Veterans dealing with polysubstance dependency involving both benzodiazepines and opioids require integrated treatment that addresses both substances simultaneously. Treating one without the other leaves the underlying risk structure intact. For a detailed discussion of this clinical challenge, see our page on co-occurring disorders in Veterans.

Treatment for Benzo Dependency: A Slow Taper Process

There is no pharmacological shortcut for benzodiazepine dependency. Unlike opioid use disorder, where medications like buprenorphine and naltrexone can stabilize the brain’s receptor system and reduce craving, benzodiazepine dependency is treated primarily through a supervised, gradual taper: a planned, stepwise reduction in dose over a period that may span weeks to months, depending on the severity of dependency and the individual’s clinical presentation.

The Ashton Manual, a clinical protocol developed by British pharmacologist Dr. Heather Ashton, remains one of the most referenced frameworks for benzodiazepine tapering. The core principle is that dose reductions must be small enough for the nervous system to adapt between steps, preventing the threshold events, particularly seizures, that occur when reduction is too rapid. Individual protocols must be built by clinicians with full knowledge of the patient’s history, current dose, and other medications.

In practice, this means the following for Veterans in residential treatment at Hope Valley:

• Conversion to a longer-acting benzodiazepine. Short-acting benzos like Xanax have a rapid rise and fall in blood levels, which creates interdose withdrawal and makes tapering harder. Converting to a longer-acting equivalent like diazepam produces more stable blood levels and a smoother taper experience.
• Individualized taper schedule. No standardized schedule works for every patient. Clinical staff assess tolerance level, duration of use, co-occurring conditions, and the Veteran’s subjective response to each reduction before determining the pace of the next step.
• Medical monitoring throughout. Vital signs, neurological status, and symptom reporting are tracked at each stage. The ability to pause, slow, or modify the taper based on clinical response is essential, and it is only possible in a residential setting where the patient is under daily observation.
• Parallel psychiatric support. As the benzodiazepine dose decreases, the underlying anxiety or PTSD that was being managed (or masked) by the medication will emerge with increasing clarity. This is not relapse or failure; it is the necessary step toward treating the underlying condition with evidence-based approaches. VA-endorsed therapies including Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE) are offered in parallel with the medical taper.
• Non-pharmacological symptom management. Sleep hygiene protocols, breathwork, mindfulness-based stress reduction, and physical activity all play supporting roles in managing the discomfort of taper and building the neurological tools that will replace what the benzodiazepine was doing.

For Veterans whose benzodiazepine dependency co-occurs with opioid use disorder, medication-assisted treatment for Veterans may be integrated into the treatment plan. Buprenorphine may be used to stabilize opioid dependency while the benzodiazepine taper is managed separately, with clinicians coordinating the two tracks to minimize interaction risk.

According to SAMHSA’s treatment guidelines, effective treatment requires a comprehensive, individualized plan that addresses all co-occurring conditions simultaneously. Hope Valley’s clinical team, operating under CARF accreditation standards, conducts a full biopsychosocial assessment at admission to ensure treatment planning reflects the complete clinical picture, not only the presenting substance. As a credentialed TRICARE provider, Hope Valley handles prior authorization and benefits verification directly, so Veterans and families can focus on care rather than paperwork.

Long-Term Recovery After Benzo Dependency

Benzodiazepine recovery extends well beyond the taper itself. The neurological changes that develop over months or years of use do not fully reverse within days of completing the taper. Post-acute withdrawal syndrome (PAWS), persistent symptoms including anxiety, cognitive fog, sleep disruption, and emotional dysregulation, can continue for weeks to months and is one of the primary drivers of return to use in this population.

These symptoms are neurologically based, not a sign of failure. Research published through NCBI on protracted benzodiazepine withdrawal confirms that most patients experience gradual improvement over months and that the prognosis for full functional recovery is good with appropriate support.

What that support looks like in practice:

• Continued psychiatric care. PTSD and anxiety disorders that were being masked by benzodiazepines will need targeted treatment, and that treatment needs to be evidence-based. Cognitive Processing Therapy and Prolonged Exposure have the strongest evidence base for PTSD. Veterans should not be returned to benzodiazepines as a default when PTSD symptoms emerge during PAWS. The goal is building genuine regulation capacity, not chemical suppression of symptoms.
• Sleep support without sedative medications. Sleep disruption during PAWS is common and distressing. Behavioral sleep interventions, particularly Cognitive Behavioral Therapy for Insomnia (CBT-I), which the VA endorses as first-line treatment for veterans, can be effective where medications create risk. Physical activity, consistent sleep-wake schedules, and reduction of stimulants are foundational components.
• Peer support from Veterans in recovery. Isolation after service is itself a risk factor for return to use. Peer support from Veterans who have navigated benzodiazepine dependency and recovery provides something clinical staff cannot: direct shared experience. Hope Valley’s programming includes Veteran peer support as a core element of the recovery continuum, not an add-on.
• Family education. Family members who understand PAWS, who know that cognitive fog and emotional variability are neurological and temporary rather than character flaws, provide a fundamentally different home environment. Family education is a standard component of the Hope Valley treatment model.
• Step-down planning. The transition from residential to outpatient care is a high-risk period, and in benzodiazepine recovery PAWS may still be active at discharge. Step-down planning includes crisis resources, scheduled psychiatric follow-up, and a named contact for emergencies, all required under CARF accreditation standards.

The long-term prognosis for Veterans who complete a medically supervised taper inside a residential program is meaningfully better than for those who attempt it in isolation or return to use because PAWS was never explained. VA whole health resources on benzodiazepine discontinuation reflect this directly: successful discontinuation is a process, not a single event, and it requires sustained support across the full recovery arc.

Veterans who have lived with benzodiazepine dependency for years sometimes find it difficult to believe that functioning without the medication is possible. Their experience of anxiety without benzos has been, until treatment, the experience of interdose withdrawal, a pharmacologically induced state that is not what natural anxiety feels like. The recalibrated brain, given time and support, does not return to where it started. For most Veterans, it returns to a state that is more functional and more capable of engaging with the evidence-based treatments for PTSD, pain, and sleep that benzodiazepines were always standing in the way of.

If you are a Veteran or a family member trying to understand whether benzodiazepine dependency is part of the problem, call Hope Valley at (907) 318-2180. The clinical team can provide a confidential assessment, answer questions about residential treatment, and walk through TRICARE benefits and coverage. Benefit verification is free and takes one business day.